| 產(chǎn)品名稱 | MK 1775 - AZD 1775 | Adavosertib |
| 產(chǎn)品貨號(hào) | Axon 1494 CAS [955365-80-7] MF C27H32N8O2MW 500.60 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description A potent and selective Wee1 kinase inhibitor in vitro and in vivo. MK 1775 abolishes cyclin-dependent kinase 1 (CDC2) activity by phosphorylation of the Tyr15 residue. It abrogates a DNA damage checkpoint (G2-phase), leading to apoptosis in combination with several DNA-damaging agents selectively in p53-deficient tumor cell lines. It is under clinical trial for advanced solid tumors. KEYWORDS: MK 1775 | supplier | Wee1 inhibitor | AZD 1775 |?Adavosertib | supplier | MK1775 | AZD1775 | CAS [955365-80-7] | CDK1 | Wee1 | Inhibitor | cyclin-dependent kinase 1 | CDC2 | DNA damage | checkpoint | G2-phase | apoptosis | p53-deficient | solid tumor |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià),電話:010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
MK 1775 - AZD 1775 | AdavosertibAxon 1494 CAS [955365-80-7] MF C27H32N8O2
DescriptionA potent and selective Wee1 kinase inhibitor in vitro and in vivo. MK 1775 abolishes cyclin-dependent kinase 1 (CDC2) activity by phosphorylation of the Tyr15 residue. It abrogates a DNA damage checkpoint (G2-phase), leading to apoptosis in combination with several DNA-damaging agents selectively in p53-deficient tumor cell lines. It is under clinical trial for advanced solid tumors. KEYWORDS: MK 1775 | supplier | Wee1 inhibitor | AZD 1775 |?Adavosertib | supplier | MK1775 | AZD1775 | CAS [955365-80-7] | CDK1 | Wee1 | Inhibitor | cyclin-dependent kinase 1 | CDC2 | DNA damage | checkpoint | G2-phase | apoptosis | p53-deficient | solid tumor ? List of publications using MK 1775 (Axon 1494) purchased from Axon Medchem
Wee1 kinase inhibitor
Chemical name2-Allyl-1-[6-(1-hydroxy-1-methyl-ethyl)-pyridin-2-yl]-6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,2-dihydro-pyrazolo[3,4-d]pyrimidin-3-one Parent CAS No.[955365-80-7] |
| 產(chǎn)品資料 |